Form 4 for SNTI Senti Biosciences Holdings, Inc.
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0001854270-25-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-07 | SNTI | Rajangam Kanya | Pres, Chief Med, Dev. Off | A - Grant | $0.00 | +78.4K | 87.0K | +909% | $0 |
| D | 2025-03-10 | 2025-03-06 | SNTI | Rajangam Kanya | Pres, Chief Med, Dev. Off | A - Grant | $0.00 | +235.1K | 235.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-07 | A | A | 78,363 | $0.00 | 86,984 | D | — | — | (F1) The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan, as amended and restated (the "Amended and Restated Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from March 7, 2025, subject to the reporting person's continued service through the applicable vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-03-06 | A | A | 235,088 | $0.00 | 235,088 | D | $3.97 · — to 2034-12-19 | 235,088 Common Stock | (F2) The option grant was approved by the Issuer's board of directors on December 20, 2024, subject to shareholder approval of the Amended and Restated Plan, under which the option was granted. The Issuer's shareholders approved the Amended and Restated Plan on March 6, 2025. (F3) Three-forty-eighth of the shares underlying this option vest on March 31, 2025 ("Vesting Commencement Date") and thereafter one-forty-eighth of the shares underlying this option vest in equal monthly installments from the Vesting Commencement Date, such that the option will be fully vested on the date forty-five months after the Vesting Commencement Date, subject to the reporting person's continued service through the applicable vesting date. |